Deciphera Pharmaceuticals, Llc

This phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…

This study tests a new drug called ripretinib against the standard drug sunitinib in people with advanced gastrointestinal stromal tumor (GIST) whose cancer worsened or who couldn't tolerate the first treatment, imatinib. About 453 adults with GIST are randomly assigned to take e…

This study tests an experimental drug called vimseltinib in people with advanced solid tumors or a rare joint tumor called tenosynovial giant cell tumor (TGCT). The goal is to find the safest dose and see if the drug shrinks tumors. About 120 adults will take part in two phases: …

This study tests a new drug, ripretinib, against the current standard sunitinib in people with advanced gastrointestinal stromal tumor (GIST) whose cancer has a specific genetic change (KIT exon 11 plus 17 or 18) and has stopped responding to the first treatment, imatinib. About …